Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo hóa học: " Abstract Despite new additions to the standard of care therapy for high grade primary malignant brain tumors, the prognosis for patients with this disease is still poor."

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành hóa học dành cho các bạn yêu hóa học tham khảo đề tài: Abstract Despite new additions to the standard of care therapy for high grade primary malignant brain tumors, the prognosis for patients with this disease is still poor. | Hickey et al. Journal of Translational Medicine 2010 8 100 http www.translational-medicine.eom content 8 1 100 JOURNAL OF TRANSLATIONAL MEDICINE REVIEW Open Access Cellular and vaccine therapeutic approaches for gliomas 1 1 12 3 3 Michelle J Hickey Colin C Malone Kate L Erickson Martin R Jadus Robert M Prins Linda M Liau Carol A Kruse 1 Abstract Despite new additions to the standard of care therapy for high grade primary malignant brain tumors the prognosis for patients with this disease is still poor. A small contingent of clinical researchers are focusing their efforts on testing the safety feasibility and efficacy of experimental active and passive immunotherapy approaches for gliomas and are primarily conducting Phase I and II clinical trials. Few trials have advanced to the Phase III arena. Here we provide an overview of the cellular therapies and vaccine trials currently open for patient accrual obtained from a search of http www.clinicaltrials.gov. The search was refined with terms that would identify the Phase I II and III immunotherapy trials open for adult glioma patient accrual in the United States. From the list those that are currently open for patient accrual are discussed in this review. A variety of adoptive immunotherapy trials using ex vivo activated effector cell preparations cell-based and non-cell-based vaccines and several combination passive and active immunotherapy approaches are discussed. Introduction The majority of primary tumors of the central nervous system CNS are of astrocytic lineage 1 . Glial tumors are typically classified based upon histologic criteria. The World Health Organization WHO classification system for primary malignant gliomas in adults has gradings that range from II to IV. The more slowly growing WHO grade II tumors are termed astrocytomas A oligodendrogliomas ODG or mixed gliomas MG . WHO grade III tumors are similarly designated but with the word anaplastic preceding the names i.e. anaplastic astrocytomas AA .